Nothing said here yet.
to join the conversation.
| Mahboob VaseemChief Financial Officer | Sell | 4,788 | $146.5K | Thu, Oct 29 |
| Mahboob VaseemChief Financial Officer | Sell | 39,903 | $1.2M | Wed, Oct 28 |
| Mahboob VaseemChief Financial Officer | Sell | 34,809 | $1.0M | Tue, Oct 27 |
| Umberger Traci SSee Remarks | Sell | 30,000 | $900.9K | Tue, Oct 27 |
| Umberger Traci SSee Remarks | Sell | 96,404 | $2.6M | Wed, Oct 21 |
| Umberger Traci SSee Remarks | Sell | 3,596 | $101.0K | Wed, Oct 21 |
| Webster Brian DanielSee Remarks | Sell | 13,316 | $393.1K | Tue, Oct 20 |
| Webster Brian DanielSee Remarks | Sell | 1,684 | $50.3K | Tue, Oct 20 |
| COHEN RAYMOND WDirector | Sell | 3,330 | $97.5K | Wed, Sep 30 |
| Kwo ElizabethDirector | Sell | 4,010 | $97.3K | Mon, Sep 21 |
| Hanley ConorDirector | Sell | 5,694 | $143.8K | Tue, Sep 8 |
| Ladone Mary KayDirector | Sell | 3,908 | $98.5K | Tue, Sep 8 |
Why Kestra Medical Technologies Stock Is Back In Focus Kestra Medical Technologies (KMTS) has drawn fresh attention after first quarter results showed sales of US$30.97 million and a net loss of US$44.09 million, alongside a higher fiscal 2027 revenue outlook.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reported on September 14 that fiscal first-quarter 2027 revenue increased 60% to $31.0 million. Gross margin reached 56.5%, up from 45.7%, for the quarter ended July 31, 2026.
Moby summary of KESTRA MEDICAL TECHNOLOGIES, LTD.'s Q1 2027 earnings call
Kestra Medical Technologies Ltd (KMTS) posted 60% revenue growth, a record 11th straight quarter of gross margin expansion, and raised its FY27 outlook on surging in-network mix and faster rep ramps.
Kestra Medical Technologies (NASDAQ:KMTS) reported first-quarter fiscal 2027 revenue of $31 million, with President and Chief Executive Officer Brian Webster saying revenue rose 60% from a year earlier and advanced sequentially from the fourth quarter.
Kestra Medical Technologies, Ltd. (KMTS) delivered earnings and revenue surprises of -22.95% and +6.66%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?